Hematological Malignancies | Norton Healthcare

Indication: Hematological Malignancies

An Open-Label Study to Assess the Anti-Tumor Activity and Safety of REGN1979, an anti-CD20 x anti-CD3 Bispecific Antibody, in Patients with Relapsed or Refractory Follicular Lymphoma


Line of Therapy: Must have relapsed or must be refractory to =2 prior lines of systemic therapy, including an anti-CD20 antibody and an alkylating agent

Drug Study

Principal Investigator: Don Stevens, M.D.
Norton Cancer Institute

Sponsor: Regeneron Pharmaceuticals, Inc.

Learn more at ClinicalTrials.gov

Email for more information: Heme-NCIResearch@nortonhealthcare.org

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.